Abstract
To determine the possible involvement of protease M/neurosin in demyelinating diseases of the CNS, we examined its expression in myelin oligodendrocyte glycoprotein -3 -Experimental autoimmune encephalomyelitis (EAE) is an inflammatory demyelinating disease of the central nervous system (CNS) induced by the active or passive immunization of susceptible strains of rodents and primates with myelin components, which is used to study human demyelinating diseases, such as multiple sclerosis (MS) [13, 14] . In C57BL/6 mice, immunization with myelin oligodendrocyte glycoprotein (MOG) induces a progressive disease, which is characterized by demyelination and inflammation in the CNS [9, 10] . Although considerable progress has been made in understanding the genetic susceptibility and pathogenesis of this disease, there is still no uniformly effective treatment strategy [15, 18] . The enzymatic digestion of the blood brain barrier and myelin protein by serine proteases is known to contribute to the development and progression of MS and EAE [1, 12, 19] . The identification and characterization of key enzymatic players may suggest new therapeutic targets.
Kallikreins are serine proteases and known to serve a variety of physiological function [3] . Protease M/neurosin is a kallikrein-like serine protease that is distributed exclusively in oligodendrocytes in the brain [21] , and KLK6 was assigned to a gene in the human genome [8, 22, 24] . Previously, several groups have reported significant reductions of human kallikrein 6 in cerebrospinal fluid and brain extracts of patients with Alzheimer's disease, suggesting that kallikrein 6 may have antiamyloidogenic potential through proteolytic activity [7, 25] . Our recent study has demonstrated that traumatic injury to the spinal cord causes changes in the expression of protease M/neurosin in oligodendrocytes and their progenitors [20] . Scarisbrick et al. [5, 16, 17] Then adjusted pH to 7.3 with 1 M Tris-HCl, pH 7.5.
Immunohistochemistry was performed using rabbit anti-protease M/neurosin antibody as described above. The method used for immunohistochemistry was described in previous papers [20, 23] . In situ hybridization was performed using a digoxigenin (DIG, Roche Molecular Biochemicals, Mannheim, Germany)-labeled cRNA probe for protease M/neurosin mRNA. The method used for in situ hybridization was described in previous papers [4, 20, 23] . Some sections were further processed for immunolabeling with the following cell-specific markers: mouse monoclonal anti-glial fibrillary acidic protein (GFAP, Sigma; 1:5,000) to identify astrocytes; mouse monoclonal anti-2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNPase, Sigma; 1:2,000) to identify mature At different time points during the course of EAE, mice (n = 3 at each time point) were given a lethal dose of anesthetic (100 mg/kg), and the spinal cord, spleen and thymus were quickly dissected. The methods used for RNA extraction and PCR was described in a previous paper [20] . The PCR primers were designed according to published sequences All animals exhibited signs of disease and developed a chronic course (Fig. 1A) . In situ hybridization and immunohistochemistry demonstrated an increase in the expression of protease M/neurosin mRNA and its protein product in areas associated with these demyelinating foci ( Fig. 2B-F) . Within untreated control mice, constitutive expression of protease M/neurosin mRNA was observed in the white matter of the spinal cord (Fig. 2B ). In mice with EAE, enhanced expression of protease M/neurosin mRNA was observed throughout the white and gray matter (Fig. 2C,   D) . Similarly, immunohistochemistry showed constitutive expression of protease M/neurosin within control spinal cord white matter and enhanced expression in areas associated with demyelinating foci (Fig. 2E, F) . At day 42 post-immunization, when there was some attenuation of the clinical symptoms and inflammatory pathology, the increased expression of protease M/neurosin still persisted (data not shown).
To determine the identity of the cells expressing protease M/neurosin mRNA in the (Fig. 3F ).
-9 -Quantitative real-time PCR analysis in the spleen demonstrated that there were no significant changes in the expression of protease M/neurosin and TNF-α mRNAs during the course of EAE (Fig. 4A, B) . In the thymus, however, protease M/neurosin mRNA expression was significantly downregulated at days 10 and 21 post-immunization while TNF-α mRNA expression was upregulated at day 21 post-immunization (Fig. 4C, D) .
This study shows an increase in the expression of protease M/neurosin mRNA and its myelin-associated glycoprotein, PLP or MOG and depending on the animal species [9] .
In the present study we also showed that levels of protease M/neurosin mRNA expression were unchanged in the spleen and even decreased in the thymus during the course of EAE.
Although the identity of the cells expressing protease M/neurosin mRNA in the spleen and thymus remains to be determined, it is likely that leukocytes including lymphocytes are not a major source of protease M/neurosin in MOG-induced EAE.
In conclusion, changes in the expression of protease M/neurosin in oligodendrocytes, their progenitors or other cell types may be involved in the pathogenesis of demyelinating diseases of the CNS. individual experiments. Statistical comparisons were made among all groups using raw data. Asterisks indicate a significant difference from naive control (ANOVA with post hoc Fisher's PLSD test), *P < 0.05; ***P < 0.001.
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